STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics

STAT PlusBiotech Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics A resolution in arbitration puts Prime in its best position in years Manage alerts for this article Email this article Share this article By Jason MastJuly 8, 2026 General Assignment Reporter Jason Mast[email protected]Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Prime Medicine said Wednesday that it had won an arbitration dispute against Beam Therapeutics, resolving for now a clash that had pitted two well-backed gene-editing companies that had been spun out of the same lab against each other. An arbitrator ruled that Prime’s work on a gene-editing drug for the rare liver disease alpha-1 antitrypsin deficiency, or AATD, did not violate a 2019 agreement designed to prevent the two companies from competing against one another.Advertisement The ruling paves the way for Prime to start a clinical trial for AATD this quarter, lifting the biotech’s stock 11% Wednesday morning. The outcome, however, is a blow to Beam Therapeutics. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, gene editing, Pharmaceuticals, STAT+ Submit a correction requestReprints Jason Mast General Assignment Reporter Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech July 7, 2026 STAT Plus: FDA approves Vera Therapeutics kidney disease treatment The Readout July 7, 2026 STAT Plus: Compass says depression drug has long-lasting benefits Advertisement Biotech July 6, 2026 STAT Plus: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms The Readout July 6, 2026 STAT Plus: Four major biotech updates to catch up on Politics July 6, 2026 STAT Plus: GOP lawmakers push Trump’s FDA to make sure clinical trials are diverse Subscriber Picks